Malignant tumours generally exhibit upregulated glycolysis and conversion to lactic acid as a result of regional hypoxia caused by disordered blood flow and aerobic glycolysis, in which anaerobic metabolism of glucose persists even in the presence of oxygen – a phenomenon termed the ‘Warburg effect’ (Warburg, 1930). Increased glucose consumption is measured by clinical imaging through positron emission tomography (PET) scanning with $^{18}$F-deoxy-o-glucose. In fact, extensive clinical experience in imaging human cancers through $^{18}$F-deoxy-o-glucose PET has demonstrated the vast majority of human malignancies exhibit increased glycolysis (Gambhir, 2002). An inevitable consequence of upregulated glycolysis is production of increased lactic acid. As a result, studies investigating the microenvironment of tumours have demonstrated a consistently low extracellular pH (pHe) – typically in the range of 6.5–7.0 (Helmlinger et al, 1997; Schornack and Gillies, 2003). Mathematical modelling of the tumour–host interface (Gatenby and Gawlinski, 1996; Smallbone et al, 2007) has predicted that intra-tumoural acidity results in proton flow along concentration gradients from the tumour into the surrounding tissue. This phenomenon has now been confirmed experimentally (Gatenby et al, 2006).

Despite the discovery of the Warburg effect nearly 100 years ago, the reason malignant tumours consistently use aerobic glycolysis has remained speculative. The advantage to the tumour cell is not obvious, as anaerobic metabolism of glucose produces only 2 ATP per glucose, as compared with 38 ATP per glucose in aerobic respiration. In addition, glycolysis produces hydrogen ions, which acidify the extracellular space. Why then, would tumours preferentially use glycolysis in well-oxygenated environments?

In previous publications, the authors suggested the glycolytic phenotype confers an evolutionary advantage for tumour cells by producing a harsh acidic environment in adjacent normal tissue, facilitating tumour proliferation and invasion by promoting normal cell death and matrix degradation (Gatenby and Gillies, 2004; Gatenby and Gillies, 2008; Gillies et al, 2008). The ‘acid-mediated invasion hypothesis’ leads to the corollary prediction that raising the tumour pHe would significantly reduce tumour growth, and perhaps inhibit the growth of metastases in mouse xenografts.
that neutralising acidic tumour pH will inhibit invasion and, subsequently, spontaneous metastases. Furthermore, such intervention strategies might be achieved with very small molecular buffers such as bicarbonate, which are much more diffusive than drug macromolecules, suggesting prospective treatments that may not suffer from the inhibitory effects of raised interstitial pressures on cross-capillary advective transport within tumours. Metastasis inhibition through tumour buffering has been confirmed experimentally through oral administration of sodium bicarbonate (NaHCO₃, pKa 6.3) to severe combined immunodeficient mice bearing MDA-MB-231 and PC3M tumours (Robey et al., 2009). However, oral bicarbonate therapy only raised tumour pH modestly, achieving an increase of ~0.1 pH unit, and did not inhibit growth of larger, primary tumours nor did it reduce metastases in highly aggressive, rapidly growing cell lines. Further, the pKa of bicarbonate in solution is 6.1, suggesting bicarbonate is a less effective buffer than a buffer with a pKa nearer to blood pH of 7.4.

The current work addresses two issues: (1) Can the experimental bicarbonate therapy results be safely and effectively translated into clinical application as a therapeutic intervention against malignant cancer? (2) Can tumour pH normalisation be enhanced or more safely delivered through strategies that increase buffer concentration, improve buffering capacity, decrease H⁺ production or excretion, or use buffers of a more optimal pKa? We use a mathematical model of blood and tumour buffering (Martin et al., 2011) to recapitulate the previous experimental results in mice bearing metastatic MDA-MB-231 breast tumour xenografts, verifying our model predictions against observed pH measurements taken using fluorescence ratio imaging of SNARF-1 in a dorsal skin-fold window chamber. We then use in vivo studies to test a key model prediction, and predict the translational efficacy in humans. Our modelling predicts effective clinical treatments can be achieved using combination therapies, suggesting promising avenues for new discoveries.

MATERIALS AND METHODS

Mathematical model

To examine the effect of buffer administration on blood and tumour pH, we apply and draw clinical insights from a previously developed simple, but realistic mathematical model of the CO₂/HCO₃⁻ buffer system present in blood and tissues. In this analysis, we examine the impact of administration of bicarbonate on blood and tumour pH in mice and humans. A schematic of the model is shown in Figure 1, details of the model and model verification are presented in the Supplementary Appendix, and a full mathematical asymptotic analysis examining the fast, medium and steady-state dynamics can be found in Martin et al. (2011).

We use a two-compartment model, representing, respectively, the arterial blood and tumour tissue with a diffusively dominated transport coupling given the small molecules under consideration (consistent with the conclusions that small hydrophilic molecular transport is diffusion dominated in the special case of brain tumours (Groothuis et al., 1982; Jain, 1987)). The aim is to develop a simple but realistic model of pH at the tumour and blood compartment scale, which accurately models the physiological regulation of tumour and blood pH. The compartments are represented through coupled ordinary differential equations, which neglect spatial variations. The rationale for this model is predicated on blood being well mixed, and that we are interested in the average tumour pH, rather than smaller scale spatial heterogeneities. As we ignore spatial gradients, we use an averaged proton production term across the tumour. This allows us to neglect the role of heterogeneity in oxygen consumption, especially as tumour cells exhibit the glycolytic phenotype even in the presence of oxygen.

Numerical simulations and parameterisation

The system of equations is solved in MATLAB using the stiff solver ode 15s, a variable order multistep solver. Initial conditions are normal arterial biological values of the variables (pCO₂ = 40 mm Hg, HCO₃⁻ = 24 mmol l⁻¹, and pH = 7.4). Mouse and human parameters used for the simulations are listed in Supplementary Appendix Table 1. Physiological parameters (such as those involved with ventilation and kidney filtration) and kinetic parameters (such as reaction coefficients) are derived from experimental literature. The tumour acid-production rate is determined by requiring a baseline tumour pH of 7.0 as found in Robey et al. (2009). For more details on parameterisation, see Martin et al. (2011).

Model verification with bicarbonate administration in mice

To verify whether the model accurately predicts tumour pH with bicarbonate therapy, we estimate the tumour pH with the bicarbonate dose administered in the Robey et al. (2009) study of 36 mmol kg⁻¹ per day (an average of 4.2 ml per day per mouse consumption of 200 ml bicarbonate water, and average mouse weight of 23 g). Model predictions were compared with the experimentally observed pH, which was monitored using fluorescence ratio imaging of SNARF-1 in the dorsal skin-fold window chamber tumour xenografts (Robey et al., 2009).

Model prediction of equivalent dose administration in humans

To examine whether the buffering impact seen in the Robey et al. (2009) study in mice would be achievable with the same equivalent dose in humans, we simulate the buffer therapy with human
parameters and translate the bicarbonate dose. Dose translation from mice to humans is calculated from the Du Bois height–weight formula to predict surface area: BSA (m²) = 0.007184 × height (cm)0.725 × weight (kg)0.425 (Freireich et al, 1966; Reagan-Shaw et al, 2008).

Animal experiments to determine whether systemic pH is elevated in bicarbonate-treated mice

The effect of bicarbonate on blood pH was indirectly measured by sampling urine pH in tumour-bearing mice. It is well established that a rise in blood pH because of bicarbonate loading causes a proportionally larger rise in urine pH (Pitts and Lotspeich, 1946; DuBose, 1982; Nijenhuis et al, 2006). Hence, small changes in blood pH can be monitored via the urine pH. All animals were maintained under Institutional Animal Care and Use Committee approved protocols at the University of Arizona. In accordance with previous investigations (Robey et al, 2009), six- to eight-week-old female severe combined immunodeficient mice (n = 20) received orthotopic injections of 5 × 10⁶ MDA-MB-231 tumour cells in a mammary fatpad. Animals were monitored and maintained by the Experimental Mouse Shared Services core facility of the Arizona Cancer Center, Tucson Arizona. Six days after injection, mice were randomised into two groups (n = 10 in each group): the control was provided drinking water and the treated was provided sodium bicarbonate (200 mmol l⁻¹) ad libitum, which continued for the duration of the experiment (3 weeks). At intervals, mice from both groups were removed for collection of urine specimens to obtain pH measurements. This was achieved by applying gentle pressure to the abdomen over a plastic membrane.

Statistics

Statistical calculations were determined using the analysis feature in GraphPad Prism version 4.03. for Windows (GraphPad Software, San Diego CA, USA, http://www.graphpad.com). Unpaired, two-tailed t-tests were used to determine if means of urine pH (found experimentally as described above) at each sample time-point (0, 0.25, 1, 2, 5, 7, 12 and 21 days after treatment initiation) were significantly different between untreated and treated groups. A P-value of < 0.05 was considered to be statistically significant. Data are represented as mean ± s.e.m.

Model extension to predict the ideal pKa for an alternative buffer

To explore the efficacy and characteristics of an alternative hypothetical buffer (which would ideally have a greater tumour buffering impact and result in less blood pH change), we develop an extended mathematical model, incorporating the administration and reaction kinetics of a hypothetical exogenously administered buffer. The equations and parameters for this system are detailed in the Supplementary Appendix.

Assessing clinical implications of model sensitivity

To determine promising combination therapies and potential patient groups who would benefit from treatment, we analyse results of a one-way sensitivity analysis (Martin et al, 2011), and perform further simulations to predict clinical impact in humans.

RESULTS

Simulations results: bicarbonate raises both tumour and blood pH, and the model correctly simulates the mouse tumour pH increase found experimentally

In mouse and human simulations, administration of bicarbonate raises both the tumour and blood pH (Figure 2). Using the
estimated consumed dose of 36 mmol kg$^{-1}$ per day from Robey et al (2009), simulations predict an increase of 0.07 pH units in the mouse tumour (from 7.0 to 7.07). This agrees with the observed pH change recorded using imaging of SNARF-1 in a dorsal skinfold window chamber, with a mean (s.e.) pH of the peri-tumoural tissue of 7.0 (0.04) in the control group, and 7.07 (0.03) in the treated group (Figures 3A and B). However, simulations predict bicarbonate raises blood pH by a smaller relative magnitude (0.04 and 0.07 pH units in mouse blood and tumour, respectively; 0.02 and 0.04 pH units in human blood and tumour, respectively).

Experimental results: oral administration of bicarbonate consistently elevates urine pH in mice

Before initiation of bicarbonate therapy, the urine pH was not statistically different between each group ($P = 0.3$). The elevated urine pH in the bicarbonate treatment group was observable at the first data point after treatment initiation (6 h, $P < 0.001$ as compared with the untreated group at $t = 6$ h, $P < 0.001$ as compared with treatment group at $t = 0$). As shown in Figure 3C, the urine pH in the treatment group as compared with the untreated group remained significantly elevated at each sample time-point through the duration of the study (21 days; $P < 0.001$ at hour 6, $P = 0.02$ at day 1, $P = 0.01$ at day 2, $P < 0.001$ at day 5, $P < 0.001$ at day 7, $P < 0.001$ at day 12, $P = 0.04$ at day 21).

Similarly, the urine pH of the treated group remained significantly ($P < 0.01$) elevated at each sample time-point as compared with before treatment initiation (at $t = 0$).

The relationship between urine and blood pH is approximately linear in the range studied, but can vary depending on levels of potassium and other ions not measured in this study. Assuming normal ion levels, an estimate for the urine–blood pH slope can be obtained from a previous bicarbonate-loading study in mice (Nijenhuis et al, 2006). Using this slope and assuming a normal, untreated baseline blood pH of 7.4, the treated urine pH measurements correspond to an average estimated blood pH of 7.44 ± 0.02.

Simulation results: increased bicarbonate dose will be necessary in humans to achieve equivalent tumour pH elevation, but careful dose monitoring is necessary due to potential blood pH deregulation

An equivalent dose to mice maintained daily on 200 mM sodium bicarbonate (∼36 mmol kg$^{-1}$ per day) is approximately 12.5–15.0 g per day in a 70 kg human. Simulations indicate the equivalent human bicarbonate dose will have a substantially lower quantitative effect than in mice (rising the tumour pH to 7.04 in

---

**Figure 3** Experimentally derived tumour and urine pH measurements for bicarbonate-treated and control mice. (A) Imaging of the window chamber showing the tumour with abundant vascularisation. The pH measurements were taken along radial lines indicated in white. (B) Window chamber least-squares fit across all directions and with all tumours showing pH distributions along radial lines for control untreated and bicarbonate-treated tumours. The horizontal axis represents the radial distance from the core of the tumour, with the tumour rim indicated by the vertical black line at ~1.4 mm. Note the raised tumour pH in the buffered mouse and the acidic pH in the interior of the tumour, with a gradient leading out into the normal tissue. The mean (s.e.) pH is 7.0 (0.04) and 7.07 (0.03) for the untreated and treated tumours, respectively (reported in Robey et al (2009)). The pH is determined using fluorescence ratio imaging of SNARF-1 as described in Robey et al (2009). (C) Average urine pH (vertical axis) for untreated (blue circles) and bicarbonate-treated (red squares) mice through time measured in days (horizontal axis). Measurements were taken at just before treatment (indicated as day 0) and then 6 h after treatment initiation (day 0.25), which already showed a significant rise in urine pH for the treated mice. Bicarbonate-treated mice show a consistently elevated urine pH. The mean pH is shown (circle/square) with the mean ± standard error indicated by a bar and vertical line. Figures (A and B) are adapted with permission from Cancer Research (Robey et al, 2009). The colour reproduction of this figure is available at the British Journal of Cancer online.
humans vs 7.07 in a mouse), shown in Figures 2 and 4. This highlights the potential need for an increased dose, alternate buffer or combination therapy.

To examine the safety for various doses of chronically administered bicarbonate in humans, we predict dose response curves with respect to blood pH. As the human body is resilient to altered CO₂ or bicarbonate levels, we focus primarily on the dangers of altered blood pH. An optimal treatment would maintain the blood pH within normal levels (7.35–7.45) but raise tumour pH to normal levels (7.2–7.4). Predicted dose response plots are shown in Figure 5A.

Metabolic alkalosis is characterised by a blood pH of above 7.45 (13, 14). In order to maintain the blood pH below 7.46, the model predicts a maximum dose of 35 g per day of bicarbonate for a 70 kg human, leading to a tumour pH of 7.10. Maximum daily dose recommendations of oral administration of bicarbonate are around 5 level teaspoons per day, or around 20–25 g per day, and little is known about the safety of long-term chronic ingestion of bicarbonate above this level. The modest predicted tumour pH change in humans at the maximum safe dose emphasises the importance of using bicarbonate in conjunction with other therapies.

Simulation results: the optimal pK of an alternative systemic pH buffer is between 7.1–7.2, but may require higher doses

If the alternative buffer is administered as a solution of acid and conjugate base, titrated to the blood pH of 7.4, it will increase the buffering capacity of the blood. In contrast to bicarbonate therapy, the model predicts it will not raise the blood pH, and could hypothetically be given at much higher doses. Simulations indicate the ideal buffer pKa is halfway between the pH of the tumour and the blood; for a blood pH of 7.4 and tumour pH of 6.8–7.0,

Figure 4

Figure 5

(A) Simulated bicarbonate dose response plot in humans, noting the change in pH of the blood (grey crosses) and tumour (black diamonds). The black horizontal lines denote the region of normal blood pH. At a dose of about 35 g of bicarbonate, the predicted tumour pH is elevated to 7.10, with a blood pH of just below the threshold of systemic alkalosis. Any dose higher than this will potentially elevate the blood pH into a dangerously high level. (B) Predicted effect of proton reduction (where the x axis is percent reduction in tumour proton production rate) via a proton inhibitor without bicarbonate (grey squares) or with bicarbonate treatment (black stars). Reducing proton production elevates tumour pH, but reduces bicarbonate effectiveness. Nevertheless, the net effect of combination therapies that reduce proton production and buffer the tumour could raise the tumour pH above an ‘acidic threshold’ to promote normal stromal cell function. (C) Blood and tumour proton reduction with bicarbonate treatment in young humans (‘young’), elderly patients with mild renal impairment (‘elderly’) and those with chronic renal failure (‘renal failure’). Although the untreated blood is more acidic in patients who are elderly or with chronic renal failure, decreased renal function causes an increased treatment efficacy.
the optimal buffer pK is 7.1–7.2 (Figure 6A). At equivalent concentrations, bicarbonate is predicted to be more effective at raising tumour pH than a buffer of pKa 7.2, but bicarbonate elevates blood pH, unlike the alternate buffer (Figures 6B and C). Hence, higher concentrations of alternative buffers may be required, even at an ideal pKa.

**Simulation results: combination therapy targeting kidney filtration will increase therapy efficacy as well as raise tumour pH**

A sensitivity analysis of the mathematical model indicates kidney filtration terms have the largest effect on tumour pH (Supplementary Appendix). Consequently, the most effective bicarbonate combination therapy would reduce glomerular filtration rate (GFR) or increase the renal acid secretion rate. Targeting these processes would not only raise the tumour pH, but also increase bicarbonate therapy efficacy due to increased bicarbonate retention.

**Simulation results: elderly patients with renal impairment or renal failure will exhibit an enhanced response to therapy**

Based on the sensitivity analysis indicating the importance of renal function on tumour pH, we examine the potential treatment effect in elderly patients with impaired renal function, and also in patients with chronic renal failure.

As elderly patients traditionally experience a reduction in blood pH due to nephron death, we simulate bicarbonate administration in a human with impaired renal function. The standard GFR for an elderly patient is 80 ml min$^{-1}$, corresponding to a 35% loss in nephron number and equivalent reduction in acid secretion rate (Hoang et al., 2003). With these reductions, the model predicts an increase in therapy efficacy, and a reduction in total tumour pH (Figure 5C).

Typical chronic renal failure GFR values are 25–35 ml min$^{-1}$, indicating a 75% loss in nephron number and corresponding reduction in acid excretion (Vander, 1980). Simulations with this impairment correctly predict a mild acidosis, with a blood pH of 7.24, a reduced (70% of normal) bicarbonate level and normal CO$_2$ levels, which mirror clinical observations (Singh and Williams, 2008). With the addition of bicarbonate therapy, the model predicts a reduction in blood protons, and an even larger tumour proton reduction (Figure 5C).

**Simulation results: combination therapy targeting tumour proton production (such as dichloroacetate to reduce glycolysis) will selectively raise tumour pH**

The sensitivity analysis also indicates that tumour pH, but not blood pH, is sensitive to tumour proton production. Therefore, any agents targeting tumour acid production will selectively lower tumour pH, with little to no effect on blood pH. One potential drug that selectively lowers tumour acid production is dichloroacetate. Dichloroacetate (DCA) is an analogue of acetic acid that increases the flux of pyruvate into the mitochondria, promoting glucose oxidation over glycolysis. Experimental studies have shown DCA selectively targets tumour cells, decreasing acid production and inducing apoptosis in vivo and in vitro (Bonnet et al., 2007; Michelakis et al., 2008). These two mechanisms serve to decrease overall tumour acidity.

In combination, simulations with bicarbonate and proton inhibition (such as through the administration of DCA) show additive beneficial effects (Figure 5B). Although the proportional efficacy of bicarbonate is lessened with the reduction in proton production by DCA, the net result is an increase in tumour pH.

**DISCUSSION OF MATHEMATICAL AND IN VIVO RESULTS**

Our modelling results are consistent with experimental observations that bicarbonate acts as an effective agent to raise tumour pH and there exists significant therapeutic potential of chronic oral bicarbonate therapy. Our study further determines: the translational safety and efficacy in humans; who might benefit the most from bicarbonate therapy; and how buffer therapies might be improved through combination or alternative buffers to decrease intra- and peri-tumoural acidosis. Our model predicts limited impact in humans using equivalent doses of bicarbonate therapy as previously used successfully in mice to prevent metastases. This would be especially true in the case of tumours producing higher concentrations of extracellular acidity; earlier calculations determined that our experimental doses are not saturating and would only be able to counteract the acid production of a 1-mm$^3$ tumour (Robey et al., 2009).

High bicarbonate doses in humans could substantially raise tumour pH, but may dangerously elevate blood pH, thus chronic administration in humans should be closely monitored. Our modelling and in vivo experiments are broadly in agreement concerning pH, predicting roughly the same tumour pH increase with chronic bicarbonate therapy in mice, and indicate chronic bicarbonate therapy raises blood pH. Although our previous study (Robey et al., 2009) recorded no blood pH increase, only one measurement was taken at the end of the experiment. Our results conflict with other theoretical models (Silva et al., 2009), which predict no change in systemic pH with bicarbonate administration; however, their model assumes a closed bicarbonate-buffering system in blood, neglecting ventilation and kidney filtration, which are crucial to systemic buffer regulation.
Our simulations predict the use of alternative buffers with a pK of 7.1–7.2 and titrated to a pHe of 7.4 would have negligible effects on blood pHe while reducing tumour acidity. However, modelling indicates these buffers would have to be administered at higher concentrations than bicarbonate to have a similar effect, as ventilation serves to increase bicarbonate-buffering efficacy. A recent study found chronic ingestion of 200 mM solution of a non-volatile buffer, IEPA (pK a 6.9), was effective at reducing metastases in a PC3M mouse model, but resulted in only a marginal increase in tumour pH (Ibrahim Hashim et al., 2011). The use of alternative buffers such as IEPA, with a pK a nearer to the optimal range predicted by the modelling, could provide a beneficial rise in tumour pH without the potential dangers of bicarbonate therapy.

Combination therapy targeting renal filtration could increase therapy efficacy and raise tumour pH. Some potential drugs that lower GFR are non-steroidal anti-inflammatory drugs (such as aspirin, ibuprofen and naproxen), and angiotensin-converting enzyme inhibitors (commonly prescribed for high blood pressure). As it is highly probable that late middle-aged and elderly patients will already be on these drugs, it is likely that the bicarbonate therapy would have a better effect on them. The use of drugs modifying renal filtration is likely to have significant side effects as well such as electrolyte imbalance, so treatments should be monitored closely. It is also important to note that the blood pH may be exquisitely sensitive to renal function (Supplementary Appendix), and therefore any use of these treatments will cause alterations in blood pH, which will need to be thoroughly investigated.

Aging and other diseases that affect renal function contribute to higher concentrations of protons in the blood supply. These physiological states would hypothetically be advantageous for users of oral bicarbonate to treat acid-producing cancers because our model indicates they could tolerate higher and more effective doses with lower risk of developing systemic alkalosis. One study reports good tolerance of a chronic high dose (60 g per day) oral administration of sodium bicarbonate in a 79-year-old man with metastatic renal cancer, though blood pH measurements were not reported (Silva et al., 2009). It should be stressed that with the enhancement of bicarbonate therapy under these conditions, patients would likely be subject to other complications or adverse events that should be monitored and investigated thoroughly.

Drugs inhibiting tumour proton production will substantially reduce H+ concentrations in tumours. Our model indicates that inhibition of tumour proton production by a relatively small amount could cause substantial reductions in tumour acidity, without any adverse effects on blood pH. A reagent like DCA fits this criterion because it can reduce extracellular tumour acidity by inhibiting lactic acid production. Moreover, DCA has been shown to selectively target tumour cells (Bonnet et al., 2007; Michalakis et al., 2008). Our preliminary in vivo and in vitro experiments using MDA-MB-231 cell lines show that hypoxia could minimise the beneficial impact of DCA as a buffer in this cell type (Robey and Martin, 2011), but other experiments should be performed in cell lines known to respond to DCA, such as A549 and MCF-7. Furthermore, the efficacy of DCA in humans is unclear, and it is important to note that DCA could have possibly serious side effects.

There are a number of limitations of this study. First, the predictions of buffer impact on tumour pH in humans are based on theoretical modelling predictions and not clinical data. In addition, the mouse dose used in Robey et al (2009) study was converted to an equivalent human dose to estimate whether this dose would result in a similar buffering impact. Although translation using allometric inter-species scaling is widely used, it is a crude approach and results should be interpreted cautiously. However, our subsequent estimations of maximally tolerable dose and impact do not rely on this scaling.

Second, our experimental data for the impact of bicarbonate on urine pH in mice only used one tumour type (MDA-MB-231). The bicarbonate-buffering effect is likely to vary between different tumour types. In our experiments, we use a spontaneously metastatic, highly aggressive tumour model. Therefore, experiments using a less aggressive cell line such as MCF7 could overestimate the potential bicarbonate benefit, but the true effect is unknown as bicarbonate buffering has not been examined in many cell lines. Previous bicarbonate-buffering experiments (Robey et al., 2009) also found a bicarbonate effect following tail vein injection of luciferase-expressing PC3M human prostate cancer cells, but no impact using B16 mouse melanoma tumours. Further experiments are needed to determine which cell lines exhibit a response to bicarbonate therapy, and why.

Chronic oral bicarbonate clinical studies have previously been conducted, but not in cancer patients. In these studies, the doses and durations ranged from 12.6 g per day for 46 days to 1.8 g per day for 2 years (de Brito-Ashurst et al., 2009; Lemann et al., 1965). Clinical trials for oral bicarbonate safety and efficacy in cancer patients are in progress, with the aim to measure dose tolerance and pain intensity over a 4-week-period. A second trial is being planned to assess the feasibility of subjects consuming chronic amounts in a 6-month-period up to the doses discussed in this article.

There is a compelling relationship between the adverse tumour microenvironment and cancer progression. Malignant tumour cells have a critical role in modulating the extracellular environment and there is evidence that this is advantageous for tumour invasion and metastases. The findings presented here show how the administration of exogenous buffers could modify the tumour microenvironment in humans, specifically in terms of pH. We elaborate how this process has limitations and may introduce other dangers, but suggest that modest changes in tumour pH may be sufficient in some cases or helpful in other circumstances to reduce chemoresistance to specific therapies that are stifled by tumour acidity.

ACKNOWLEDGEMENTS

NKM acknowledges that this work was funded by the National Cancer Institute, NIH grant U56CA113004. IFR acknowledges that this work was funded by the National Centers for Complementary and Alternative Medicine, NIH grant K01AT004678. PKM was partially supported by a Royal Society Wolfson Research Merit Award. RAG and PKM were partially supported by NIH grant 1U54CA143970-01.

Conflict of interest

The authors declare no conflict of interest.

Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc)
Bicarbonate supplementation slows progression of CKD and improves nutritional status. *J Am Soc Nephrol* **20**: 2075–2084

DuBose T (1982) Hydrogen ion secretion by the collecting duct as a determinant of the urine to blood PCO2 gradient in alkaline urine. *J Clin Invest* **69**: 145–156

Freireich E, Gehan E, Rall D, Schmidt L, Skipper H (1966) Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. *Chemother Chemother Rep* **50**: 219–244

Gamblhir SS (2002) Molecular imaging of cancer with positron emission tomography. *Nat Rev Cancer* **2**: 683–693

Gatenby RA, Gawlinski ET (1996) A reaction-diffusion model of cancer invasion. *Cancer Res* **56**: 5745–5753

Gatenby RA, Gawlinski ET, Gmitro AF, Kaylor B, Gillies RJ (2006) Acid-mediated tumor invasion: a multidisciplinary study. *Cancer Res* **66**: 5216–5223

Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? *Nat Rev Cancer* **4**: 891–899

Gatenby RA, Gillies RJ (2008) A microenvironmental model of carcinogenesis. *Nat Rev Cancer* **8**: 56–61

Gillies RJ, Robey I, Gatenby RA (2008) Causes and consequences of increased glucose metabolism of cancers. *J Nucl Med* **49**: 245–425

Groothuis D, Fischer J, Lapin G, Bigner D, Vick N (1982) Permeability of different experimental brain tumor models to horseradish peroxidase. *J Neurosurg Exp Neurol* **41**: 164–185

Helmlinger G, Yuan F, Dellian M, Jain RK (1997) Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. *Nat Med* **3**: 177–182

Hoang K, Tan J, Derby G, Blouch K, Masek M, Ma I, Lemley K, Meyers B (2003) Determinants of glomerular hypertension in aging humans. *Kidney Int* **64**: 1417–1424

Ibrahim Hashim A, Cornell N, Coelho Ribeiro MD, Abrahams D, Cunningham J, Lloyd M, Martinez G, Gatenby R, Gillies R (2011) Reduction of metastasis using a non-volatile buffer. *Clin Exp Metastasis* **28**: 841–849

Jain RK (1987) Transport of molecules across tumor vasculature. *Cancer Metastasis Rev* **6**: 559–593

Lemann J, Lennon EJ, Goodman AD, Litzow JR, Relman AS (1965) The net balance of acid in subjects given large loads of acid or alkali. *T J Clin Invest* **44**: 507–517

Martin NK, Gaffney EA, Gatenby RA, Robey IF, Gillies RJ, Maini PK (2011) A mathematical model of tumour and blood pH regulation: the HCO3-/CO2 buffering system. *Mathematical Biosci* **230**: 1–11

Michelakis ED, Webster L, Mackey JR (2008) Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. *Br J Cancer* **99**: 989–994

Nijenhuis T, Renkema KY, Hoenderop JG, Bindels RJM (2006) Acid-base status determines the renal expression of Ca2+ and Mg2+ transport proteins. *J Am Soc Nephrol* **17**: 617–626

Pitts RF, Lotspeich WD (1946) Bicarbonate and the renal regulation of acid balance. *Am J Physiol* **147**: 138–154

Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. *FASEB J* **22**: 659–661

Robey IF, Baggett BK, Kirkpatrick ND, Roe DJ, Dosescu J, Sloane BF, Hashim AI, Morse DL, Raghunand N, Gatenby RA, Gillies RJ (2009) Bicarbonate increases tumor pH and inhibits spontaneous metastases. *Cancer Res* **69**: 2260–2268

Robey IR, Martin NK (2011) Bicarbonate and dichloroacetate: evaluating pH altering therapies in a mouse model for metastic breast cancer. *BMC Cancer* **11**: 235

Schornack PA, Gillies RJ (2003) Contributions of cell metabolism and H+ diffusion to the acidic pH of tumors. *Neoplasia* **5**: 135–145

Silva A, Yunes J, Gillies RJ, Gatenby RA (2009) The potential role of systemic buffers in reducing intratumoral extracellular pH and acid-mediated invasion. *Cancer Res* **69**: 2677–2684

Singh A, Williams G (2008) *Textbook of Nephro-Endocrinology*. Academic Press: San Diego, CA

Smallbone K, Gatenby RA, Gillies RJ, Maini PK, Vaughan DJ (2007) Metabolic changes during carcinogenesis: potential impact on invasiveness. *J Theor Biol* **244**: 703–713

Vander A (1980) *Renal Physiology*. McGraw-Hill Medical Book Company: New York, NY

Warburg O (1930) *The Metabolism of Tumors (English translation by F. Dickens)*. Constable Press: London

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.

© 2012 Cancer Research UK